The revolution will be open-source: how 3D bioprinting can change 3D cell culture

Robert D. Bruno, John Reid and Patrick C. Sachs

Comment on: Consistent and reproducible cultures of large-scale 3D mammary epithelial structures using an accessible bioprinting platform by Reid et al. Breast Cancer Research. 2018; 20:122. https://doi.org/10.1186/s13058-018-1045-4

The development of three-dimensional culture scaffolds represents a revolutionary step forward for in vitro culture systems. Various synthetic and naturally occurring substrates have been developed that support 3D growth of cells. In most fields, including mammary gland biology and tumorigenesis, the two most common substrates used are the basement membrane rich extracellular matrix (ECM) isolated from Engelbreth-Holm-Swarm (EHS) mouse sarcomas (e.g. Matrigel) and collagen extracted from rat-tails. The processes of 3D culture in these two substrates has remained unchanged for nearly half a century: cells are either mixed with unpolymerized matrix to disperse them randomly throughout the substrate upon polymerization or overlaid randomly on top of a preformed hydrogel. While effective in generating organoid/tumoroid structures, the random nature of these processes has many drawbacks that limit the reproducibility and tunability of the experimental design. Furthermore, random cellular distributions limit the utility of these substrates for studying interactions within the cellular microenvironment, which have been shown to be critical for the control of stem and cancer cell function [1].

To overcome these issues, computer numerically controlled (CNC) devices can be adapted to precisely control cellular deposition within hydrogels. An example of these devices can be found in the three-axis control of modern 3D fusion deposition method (FDM) printers. Despite a rapid drop in cost of 3D printing technology, printers specifically engineered for bioprinting purposes generally remain unattainably expensive for general biological research laboratories. Thus the technology has been limited to specific biofabrication applications in specialty biomedical engineering laboratories. Furthermore, commercially available bioprinters are exclusively designed for printing “bioinks” (unpolymerized scaffoldings with or without cells) into shapes. While potentially useful for medical reconstructive procedures, the shape of the hydrogel is meaningless to cell biologists seeking to understand basic questions of cell biology, or for engineering applications seeking to direct specific differentiation of cells.

To this end, we recently developed a low-cost open access 3D bioprinting system that can be used for scientists applications (Figure 1) [2]. The printer is an open source

Figure 1: Custom benchtop 3D bioprinter and its application for printing large mammary organoids.
Top: Image of an example 3D bioprinter constructed off of the Felix 3.0 (FELIXrobotics, NL) platform. Middle: Example of coordinated print of clusters of red fluorescent protein (RFP) labeled MCF12a cells at distances of 200µm in linear array. Image taken 24 hours post-print. Scale bar = 200µm. Bottom: Mature organoid (21 days post-print) formed from coordinated print of clusters of RFP MCF12a cells into a circular array. Resulting organoids have been shown to have contiguous lumens stretching > 3mm in length.
In an era of poor data reproducibility in science [5], instruments and methods designed to limit lab-to-lab variability are in need. The open source nature of our bioprinter helps facilitate standardization of experimental parameters across laboratories. This is because the machine instructions or GCODE generated for printing experiments can be shared once data is published. We have shared our files through our website www.odustemcell.org. Researchers can go to this website, download the files needed to print their own bioprinter, and then use the GCODE files necessary to repeat our experiments exactly using their own bioprinter. While this certainly doesn’t eliminate all inter-laboratory variability, it helps simplify the process of reproducing an experiment.

Our current focused application of this printing technology is to understand the role of the cellular microenvironment in controlling differentiation of stem and cancer cells (Reid et al., Submitted). We have explored this topic in in vivo models [6–10], but our bioprinting platform allows for mechanistic insights into the process. These studies are ongoing, but one can imagine our printing platform can be used to improve any application where the random nature of traditional 3D culture is a confounding variable. And, one could argue, nearly every study is potentially confounded by this factor.

A common issue with modern science/scientist is the tendency to assign radical ideas to the “science fiction” classification; however, bioprinting needs not be the stuff of science fiction. Our studies highlight the ease of access and the utility of the technology for basic cell and cancer biology studies. Thus, we hope to lower the bar of entry further by developing easier-to-access solutions, such as ready built kits, and a graphic user interface (GUI) to simplify the experimental programming. The system offers a potentially revolutionary step forward for 3D culture models of development and cancer.

Robert D. Bruno: School of Medical Diagnostic & Translational Sciences, Old Dominion University, Norfolk, VA, USA
Correspondence to: Robert D. Bruno, email rbruno@odu.edu

Patrick C. Sachs: School of Medical Diagnostic & Translational Sciences, Old Dominion University, Norfolk, VA, USA
Correspondence to: Patrick C. Sachs, email psachs@odu.edu

Keywords: 3D bioprinting; 3D culture; mammary gland; breast cancer; open-source
Received: April 03, 2019
Published: July 30, 2019

REFERENCES

1. Bruno RD, Smith GH. Semin Cell Dev Biol. 2012; 23:591-598. https://doi.org/10.1016/j.semcdb.2012.03.007. [PubMed]
2. Reid JA, et al. Biofabrication. 2016; 8:025017.
3. Petrella RA, et al. J Neural Eng. 2018; 15:056021. [PubMed]
4. Reid JA, et al. Breast Cancer Research. 2018; 20:122. [PubMed]
5. Baker M. Nature. 2016; 533:452-454. [PubMed]
6. Booth BW, et al. Proc Natl Acad Sci U S A. 2008; 105:14891-14896. [PubMed]
7. Bruno RD, et al. Scientific Reports. 2017; 7:40196. [PubMed]
8. Sachs PC, et al. Cell and Tissue Research. 2012; 349:505-515. [PubMed]
9. Zhao M, et al. Cancer Biol Ther. 2012; 13:782-792. [PubMed]
10. Sachs PC, et al. J Biol Eng. 2017; 11:34. [PubMed]

Copyright: Bruno et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.